Troglitazone is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for people with diabetes mellitus type 2.
It was patented in 1983 and approved for medical use in 1997. It was subsequently withdrawn.
1 Mechanism of action
3 Mechanisms of hepatotoxicity
6 External links
Mechanism of action
Troglitazone, like the other thiazolidinedione...